Connect with us

Asia Pacific & Australia

Article: Sri Lanka’s woes with cannabis legalisation

Published

on


Himal….

Some propose legalising marijuana production to ease Sri Lanka’s economic crisis. Yet, any move to legalise marijuana cultivation in Sri Lanka will have to overcome a long history of prohibition, social stigma and criminalisation

As Sri Lanka struggles with its worst economic crisis since its Independence, policymakers are increasingly focusing on diversifying the country’s export industries to bring in much-needed foreign exchange, to purchase essentials such as fuel and medicines. Within this context, presenting the budget for the year 2023, President Ranil Wickremesinghe announced the appointment of an expert committee to examine the possibilities of producing cannabis – locally referred to as kansa or ganja – for export purposes.

This echoes Sri Lanka’s state minister of tourism, Diana Gamage, who remains a strong advocate for legalisation and claims it will help the economy. She has earlier promised to bring in investments worth USD 2 billion for the cannabis plantation sector.

The state minister of indigenous medicines, Sisira Jayakody, in an interview stated that the expert committee has made progress and that the final draft of the legal amendments required to make cannabis available for ayurvedic exports has already been sent to the attorney general’s department. “Following the recommendations from the Attorney General, we hope to send it to the Cabinet of Ministers for approval. Once Parliament also approves, we can start this work,” Jayakody said. He further said that although both local and foreign investors had expressed their interest in cannabis cultivation in Sri Lanka, the government was yet to begin lengthier discussions with them due to legal barriers.

Sri Lanka remains strict on the use of cannabis for recreational and medicinal purposes, despite many tourist hotspots being popular havens for the consumption of cannabis and related products. While cannabis has been legalised in many countries, its cultivation and export remain controversial due to its history as an illegal drug and its potential for misuse. Further, exporting cannabis from Sri Lanka would require navigating a complex legal landscape and establishing proper regulatory frameworks to ensure compliance with both domestic and international laws. Additionally, the cultural attitudes towards drugs in Sri Lanka may pose challenges for the commercial cultivation of cannabis.  Its association with illegal drugs will also make gaining acceptance for commercial cultivation difficult. Moreover, establishing a “profitable” cannabis industry in Sri Lanka will require significant investment in infrastructure, research and development, and regulatory frameworks. This includes setting up proper growing and processing facilities, implementing quality-control measures and developing a robust supply chain to ensure that products meet international standards., It is essential to examine these questions alongside the economic viability of exporting cannabis from Sri Lanka thoroughly.

A 300-year ban

Cannabis use for medicinal purposes has been recorded in Sri Lankan history for centuries. Some claim that early writings on cannabis date back as far as 341 CE, when King Buddhadasa of Anuradhapura wrote about it in his pharmacopoeia, Sarartha Sangrahaya. In fact, Wickremesinghe, in his address to Parliament, used the Sanskrit term for cannabis, “thriloka wijayapathra” meaning “victory over three realms”.

The head of the department of crop science at the University of Ruhuna, K K I U Arunakumara, states that there is written evidence about the historical use of cannabis in local medicine: “The kings write books about local medicine. Those books state that kansa is a very valuable drug.” Negative attitudes towards cannabis use in Sri Lanka can be traced back to the country’s colonial past. The Dutch introduced the ban on cannabis use in Sri Lanka in the 17th century, which the British colonial administration subsequently renewed. “After the Dutch, the British government also banned it,”Arunakumara states “That amendment by the British is still there in the law – no Sri Lankan government has banned it. Kansa was banned because it was used. It was used because it was cultivated in the country. We can conclude then that historically, kansa was cultivated, and reasonably believe that it was at a level where it could have been exported.”

Exporting cannabis from Sri Lanka would require navigating a complex legal landscape and establishing proper regulatory frameworks to ensure compliance with both domestic and international laws.

“There are four names: kansa, ganja, cannabis and marijuana. When we call it kansa, there is a pleasantness, but that is not there when we call it ganja. People have forgotten how cannabis became ganja in Sri Lanka. There is a cultural context for this,” said Arunakumara, emphasising the need to change cultural attitudes towards cannabis by highlighting its history.

“We need to tell people the truth. Only if there is successful acceptance from society can we eventually explore its uses in the local market too,” he added.

Cannabis use in Sri Lanka has been stigmatised and continues to be seen as a social and moral issue. The National Dangerous Drugs Control Board (NDDCB) has reported that, in 2021, cannabis was the most commonly used illicit drug in Sri Lanka, with an estimated 301,898 users. The NDDCB states that as of 2020, nearly two percent of the population above age 14 used cannabis as a drug in the last 14 years.

According to the NDDCB, in 2021, the Police Narcotics Bureau recorded that possession of cannabis and Kerala cannabis led to the second and third highest percentages of drug-related arrests, after those linked to heroin. In fact, of the total 110,031 drug-related arrests in 2021, 30 percent were for cannabis possession. The grouping of cannabis with other, more dangerous drugs, such as heroin, coupled with blanket criminalisation, contributes significantly to the stigma surrounding cannabis.

Read full article

Sri Lanka’s woes with cannabis legalisation



Source link

Continue Reading

Asia Pacific & Australia

Paper – Australia: NSW cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development.

Published

on

By


An innovative New South Wales government funded statewide Cannabis Medicines Advisory Service (CMAS) operated between January 2018 and June 2022. The service provided comprehensive patient-specific and evidence-based information to support health professionals in prescribing and patient care decisions. This study aimed to describe real-world data collected by CMAS.

A sub-set of de-identified, patient-specific enquiries collected between January 2021 and June 2022 (n = 123/567; 21.7%) were analyzed using R version 4.2.1. Diagnosis, indication, and comorbidities were coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology.

Most patient-specific enquiries from medical practitioners were from general practitioners (n = 103/123; 83.7%). Female (n = 53/123; 43.1%) and male (n = 59/123; 48.0%) patients were similarly represented. Sex was not specified for 8.9% (n = 11/123) of patients. The mean age of patients was 52.1 years (range <10-90). The most common three diagnoses were osteoarthritis, anxiety, and chronic pain. Indications that were most frequently reported included chronic pain, anxiety, back pain, non-neuropathic pain, and insomnia. Comedications were most commonly non-opioid and opioid analgesics and antidepressants. Most practitioners were considering prescribing a cannabidiol (CBD) product for their patient. Cannabinoid composition selection guidance provided by CMAS was predominantly (delta-9-tetrahydrocannabinol) THC:CBD ~1:1, followed by CBD-only products. CMAS was contacted by health professionals regarding the management of potential adverse events for five patients.

The findings of this study shed light on the information medical practitioners were seeking to inform their clinical decision-making about medical cannabis and can inform the development of clinical guidance resources.

© 2024 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.



Source link

Continue Reading

Asia Pacific & Australia

Australia’s Zenith Cannabis Clinic Throws Up More Question Marks.. It Appears They Are Providing Consults But Have No TGA Approval To Prescribe

Published

on

By


Hi I noticed you had a post about Zenith clinics I recently had a run in with them as I was seeking medication.

They are a scam they take your money which was $29 for the initial consult which they say they will return it’s just a pending holding fee for the consult.

A “so called doctor gives you a call on zoom they prescribe you”.

After two weeks nothing happened I called several times and got the same person with a south African accent they keep on telling me they are waiting for TGA approval this goes on and on they say it sometimes takes a long time.

I was fed up so I called ******* scripts got a free appointment the next day she prescribed me and the TGA approval only took 48hrs and I have the product now already.

I am yet to hear back from Zenith clinic. It’s not the money as it was only $29 but it’s the deception they must be doing this to a lot of people who really need medicine. I wanted to send this as people need to be warned so they are to right decision.



Source link

Continue Reading

Asia Pacific & Australia

SOMAI Boss Says Australian Medical Cannabis Programme Is World Beater

Published

on

By


Respectfully we’d disagree – this is what he told Cannabiz Australia

 

The Australian medical cannabis industry may have its challenges, but its focus on affordable access and patient care make it a role model for the rest of the world, says SOMAÍ Pharmaceuticals chairman and CEO Michael Sassano. 

The Australian market has become one of only three significant global medical cannabis markets in the world.

Although all eyes are on the US potentially rescheduling the substance after Germany removed the narcotics label from cannabis medicines, the Australian market continues to expand faster than most because of the focus on what is best for patients and their experience.

Australia leads in cannabis choice and pricing

Doctor and patient relationships and freedom of choice for both parties help to form the foundation of a solid medical cannabis market. When the focus is on limiting access instead, problems arise.

Michael Sassano

For example, Israel only permits flower sales and limits other products, such as extracts. Germany’s market focuses on the magistral preparation of extracts with a minimal framework for different form factors like gel capsules or faster-acting excipients.

As another example, seniors in the US are a growing market that may consume cannabis in low dosages for arthritis. Their preferred administrative and dosage choice is a mild 1:50 gel capsule or edible format. With flower-only restrictions, they would have to roll a joint or use a smoking pipe instead. Massive market segments are being excluded from access because they simply don’t want to smoke.

Australia is far beyond other larger markets regarding choice with patients having close to 1,000 medical cannabis product choices. Giving options to doctors and patients is precisely what the cannabis-as-medicine movement has always been about, not a one-size-fits-all therapy program.

The country has also embraced lower consumer pricing, making daily medicine more affordable and accessible. All favourable consumer markets give patients ample choice and affordable pricing, providing access to everyday necessities.

Read the full article

When it comes to access, the rest of the world should follow Australia’s example

 



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media